GENE ONLINE|News &
Opinion
Blog

2021-10-08| Asia-PacificCOVID-19

Samsung Biologics Inks CDMO Deal with Enzolytics on HIV and COVID-19 Antibodies

by Tyler Chen
Share To
(Photo: Samsung Biologics)

U.S.-based Enzolytics this week inked a deal with one of the world’s biggest CDMO firms. Samsung Biologics will help develop and manufacture Enzolytics’s HIV and SARS-CoV-2 targeting monoclonal antibodies to accelerate the latter’s IND filing process.

 

Provide End-to-End CDMO Service

The Korean firm will provide services involving the development and manufacture of cell lines and clinical drug products. Their R&D Center located in San Francisco will manufacture a stable cell line while the Incheon headquarters will produce related trial materials.

“We chose to partner with Samsung Biologics because of Samsung Biologics’ extensive experience and expertise in developing, producing, and manufacturing Monoclonal Antibodies for Infectious Diseases and Oncology,” said Dr. Gaurav Chandra, Enzolytics’ Chief Operating Officer Research and Development. 

“This partnership marks a pivotal milestone for Enzolytics to significantly advance the clinical development of our universal, durable, broadly neutralizing Monoclonal Antibodies and reduce time to the clinic and offer the much-needed treatment for patients.”

The pair might advance the collaboration to include other products from Enzolytics.

 

Use AI to Develop Antibodies for Infectious Diseases

Enzolytics will carry out AI analysis to develop antibodies that target immutable locations on viruses that cause infectious diseases. Their antibody development on HIV therapeutics is the most advanced among all the indications. ITV-1, Enzolytics’s HIV therapeutics, is currently on trial in the EU.

The firm is also developing treatments for rheumatoid arthritis, influenza A and B, tetanus, and hepatitis (A, B, C). Now, their technology is also implemented in developing antibodies against the COVID-19 virus.

©www.geneonline.com All rights reserved. Collaborate with us: service@geneonlineasia.com
Related Post
R&D
Fifth HIV Patient Cured After Stem Cell Transplant in Germany
2023-03-01
The U.S. COVID-19 Public Health Emergency Ends in May, but FDA’s EUA Authority Remains
2023-02-01
Novavax Begins Phase 2 For COVID-19/Influenza Combination And Stand-Alone Flu Shots
2023-01-03
LATEST
OncoC4 Bags $200 Million In CTLA-4 Antibody Pact With BioNTech
2023-03-21
HHS Issues Initial Guidance on Negotiation Program as Government’s Latest Move to Reduce Drug Prices
2023-03-21
First-Ever Insect Brain Neuron Map Completed
2023-03-21
AbbVie Unveils Latest Data For Skyrizi In Difficult-To-Treat Psoriasis
2023-03-20
Sanofi Slashes Insulin Prices by Up to 78% Following Hot On the Heels of Major Competitors
2023-03-19
Novartis Snags Pediatric Brain Cancer Indication for Oncology Combination Therapy
2023-03-19
Pfizer, Astellas’ Prostate Cancer Drug Xtandi Achieves Goals In Phase 3
2023-03-19
Scroll to Top